Gabriela Wochnik-Veltrup

Title: Gabriela Wochnik-Veltrup: Innovator in Antibody Research

Introduction

Gabriela Wochnik-Veltrup is a prominent inventor based in Eching a.A., Germany. She has made significant contributions to the field of antibody research, particularly in the development of innovative therapeutic solutions for hyperproliferative diseases, including cancer. With a total of 5 patents to her name, her work is recognized for its potential impact on medical treatments.

Latest Patents

Her latest patents focus on Anti-IGF antibodies, which are fully human antibodies that bind to human IGF-1 and cross-react with IGF-2. These antibodies prevent the binding of IGF-1 and IGF-2 to the IGF-1 receptor, thereby inhibiting IGF-1 receptor-mediated signaling. Importantly, these antibodies do not bind to insulin, ensuring that the mitogenic properties of insulin remain unaffected. This innovative approach is particularly useful for treating hyperproliferative diseases, especially cancer.

Career Highlights

Throughout her career, Gabriela has worked with leading pharmaceutical companies, including Novartis AG and Boehringer Ingelheim International GmbH. Her experience in these organizations has allowed her to refine her expertise in antibody development and therapeutic applications.

Collaborations

Gabriela has collaborated with notable colleagues in her field, including Stefan Hartle and Christoph Heusser. These partnerships have contributed to her success and the advancement of her research.

Conclusion

Gabriela Wochnik-Veltrup stands out as an influential inventor in the realm of antibody research. Her innovative patents and collaborations highlight her commitment to advancing medical science and improving treatment options for serious diseases.